Related Experiment Video

Updated: Jan 6, 2026

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker
08:32

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker

Published on: December 18, 2014

23.3K

Timing of treatment with oral propranolol for infantile hemangioma

Kaizhi Zhang1, Tong Qiu1, Jiangyuan Zhou1

  • 1Division of Oncology, Department of Pediatric Surgery, West China Hospital of Sichuan University, #37# Guo-Xue-Xiang, Chengdu, 610041, China.

BMC Pediatrics
|September 24, 2025
PubMed

Insights

Starting propranolol treatment for infantile hemangioma (IH) before 70 days of age significantly improves success rates and reduces treatment duration. Early intervention is key for better outcomes in IH patients.

Area of Science:

  • Dermatology
  • Pediatrics
  • Pharmacology

Background:

  • Infantile hemangioma (IH) treatment success can be improved with early oral propranolol.
  • Optimal age thresholds for initiating propranolol therapy in IH remain under-researched.

Purpose of the Study:

  • To determine the optimal age cutoff for initiating oral propranolol treatment to maximize success rates in infantile hemangioma.
  • To identify specific age thresholds for different IH subtypes, including high-risk and segmental IH.

Main Methods:

  • Retrospective analysis of clinical data from 207 patients with infantile hemangioma.
  • Primary outcome measured was treatment success at 6-12 months post-initiation of oral propranolol.
  • Receiver operating characteristic (ROC) curve analysis was used to determine age cutoff values.

Main Results:

  • Age at treatment initiation, high-risk IH, and segmental IH were independent predictors of treatment failure.
  • Optimal age cutoff for initiating propranolol was 69.5 days for all patients.
  • Earlier treatment (before 69.5 days) yielded a 73.8% success rate versus 28.4% for later treatment, with shorter duration.

Conclusions:

  • Initiating oral propranolol for infantile hemangioma before 70 days of age is associated with higher success rates.
  • Early treatment significantly shortens the overall treatment duration for IH.
  • This early intervention is particularly beneficial for patients with segmental or high-risk infantile hemangioma.
Abstract

Keywords:
Infantile hemangiomaPropranololTimingTreatment

More Related Videos

A Modified Sonographic Algorithm for Image Acquisition in Life-Threatening Emergencies in the Critically Ill Newborn11:27

A Modified Sonographic Algorithm for Image Acquisition in Life-Threatening Emergencies in the Critically Ill Newborn

Published on: April 7, 2023

7.2K
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.4K

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.5K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
430
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
226
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.1K
Aneurysm III: Interprofessional Care01:26

Aneurysm III: Interprofessional Care

Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
233